1. See when it’s time to transition treatments and other considerations 2. A more comprehensive approach to assessing treatment response   Make timely and well-informed treatment decisions by monitoring both clinical and subclinical MS disease activity1 While clinical assessments help monitor treatment response, some disease activity can only be detected through MRI1 DISEASE ACTIVITY OCCURS ABOVE AND BELOW THE SURFACE1 Adapted with permission from Elsevier. Data suggest that MRI can identify patients experiencing inadequate treatment response within 6 to 12 months of treatment initiation.2   Learn more about detecting MS progression   Work with your patient who is experiencing inadequate treatment response to decide on a next step1,3 Important considerations when assessing DMTs include3,4 Efficacy Immune system effects Mechanism of action Duration of systemic effects Risks Side effects Patient preferences Robert Sergott, MD, Barry Singer, MD, and Lori Mayer, DNP, discuss the importance of subclinical monitoring through MRI     Watch the discussion: MRI monitoring   MS=multiple sclerosis; MRI=magnetic resonance imaging; DMT=disease-modifying treatment. References: 1. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Mult Scler Relat Disord. 2016;9(suppl 1):S5-S48. 2. Dobson R, Rudick RA, Turner B, et al. Neurology. 2014;82(3):248-254. doi:10.1212/WNL.0000000000000036. 3. Pardo G, Jones DE. J Neurol. 2017;264(12):23‍51-23‍74. doi:10.1007/s00415-017-8594-9. 4. Wingerchuk DM, Carter JL. Mayo Clin Proc. 2014;89(2):225-240.. You have received this email because you agreed to receive communications from Biogen. If you prefer not to receive further messages from this sender, please click here to unsubscribe and confirm your request.   © 2018 Biogen. All rights reserved. 08/18 FCH-US-4249 225 Binney Street Cambridge, MA 02142 800-456-2255